Genmab A/S ADR (GMAB)

$26.54 -0.36 (-1.34%)
Market Cap 16.55B
Revenue (ttm) 3.72B
Net Income (ttm) 963.00M
EPS (ttm) N/A
PE Ratio 19.35
Forward PE 22.60
Profit Margin 25.89%
Debt to Equity Ratio 0.92
Volume 1,362,300
Avg Vol 1,731,164
Day's Range N/A - N/A
Shares Out 623.51M
Stochastic %K 41%
Beta 0.86
Analysts Strong Sell
Price Target $37.55

Company Profile

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R...

Industry: Biotechnology
Sector: Healthcare
Phone: 45 70 20 27 28
Address:
Carl Jacobsens Vej 30, Valby, Copenhagen, Denmark
Night_Owl_Biotech
Night_Owl_Biotech May. 16 at 3:07 AM
The attachment compares the Year 4 (FY2029), 5-year & 10-year revenue multiples of the 5 largest commercial-stage oncology focused bios using enterprise value. The table uses enterprise value, right or wrong, because cash/debt provides meaningful portions of the cap table of all 5. The table also provides a 5-year gross margin multiple (using actual FY25 gross margin). All 5 have at least 10 analysts that provide FY26 – 30 revenue forecasts. Again, all multiples use enterprise value (not market cap). $INCY clearly trades at the lowest 5-year revenue multiple. This is likely because the patent on Incyte’s best selling therapy called Jakafi expires in December 2028. Still, decreases in Jakafi sales appear to manifest in Incyte’s FY2029 consensus. Incyte still trades at the 2nd lowest 10-year multiple. $EXEL has the highest 5-year revenue multiple in the peer group. This is not investment advice. We’re merely sharing our analysis. $JAZZ $GMAB $ONC
0 · Reply
BlackSwan13
BlackSwan13 May. 13 at 8:23 PM
$GMAB analyzing a position
0 · Reply
The_Assassin
The_Assassin May. 11 at 12:03 PM
$GMAB looks interesting
1 · Reply
Quantumup
Quantumup May. 11 at 11:18 AM
Guggenheim🏁 $BCAX Buy; $42 $GMAB - MRUS $MRK Here's what Guggenheim said in its initiation report: https://x.com/Quantumup1/status/2053796129276358965?s=20
0 · Reply
CapitalMonk
CapitalMonk May. 11 at 9:32 AM
$GMAB Price: $26.43 (-2.33%) Trend: Bearish Market Bias (7D): Bullish Bias 📈 Expected Range: ±1.13% RSI: 39.0 | Momentum: Strong Downside Volume: +217.2% vs avg Volatility: 2.07% Support: $25.34 | Resistance: $29.43 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
QuantInsider
QuantInsider May. 8 at 5:27 PM
$GMAB looking shaky post earnings Stock's down about 3.5% today after that 11% earnings drop Revenue up 25% but profit took a 73% hit thanks to those Merus acquisition costs Interesting move though Spotted 2,900 Dec 2026 $30 calls bought at the ask for around $0.9M, mostly as sweeps 14 to 16% OTM on InsiderFinance Feels like a cautious play on the long-term story With just four prints and a lot of open interest, it’s more of a watch-list situation for now Near-term, the tape's still under pressure Might be wise to wait for some price stabilization before diving in
0 · Reply
peloswing
peloswing May. 8 at 2:31 PM
$GMAB December 18th $30 calls are seeing lots of action today. Potential to double bottom with the March lows 🟢
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 7 at 3:13 PM
$GMAB Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.08 down -74.19% YoY • Reported revenue of $896M up 25.31% YoY • Genmab is maintaining its 2026 financial guidance, expecting revenue in the range of $4.1B and operating profit between $900M, as published February 17, 2026.
0 · Reply
Todd25
Todd25 May. 6 at 9:44 PM
$GMAB when earnings?
0 · Reply
JackDarwin
JackDarwin May. 5 at 7:34 AM
$GMAB Bullish Engulfing Candlestick Pattern Formed at Downtrend. Wait for the confirmation from the next day's candle.
0 · Reply
Latest News on GMAB
Capital Increase in Genmab as a Result of Employee Warrant Exercise

Tue, 12 May 2026 13:46:00 -0400 - 5 days ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab price target lowered to DKK 2,250 from DKK 2,400 at Deutsche Bank

2026-05-11T17:36:15.000Z - 6 days ago

Genmab price target lowered to DKK 2,250 from DKK 2,400 at Deutsche Bank

Genmab (GMAB) Reports Significant Shareholding by Orbis Investment Management

2026-05-09T00:39:12.000Z - 9 days ago

Genmab (GMAB) Reports Significant Shareholding by Orbis Investment Management

Genmab announces 5.08% stake by Orbis Investment

2026-05-08T23:16:55.000Z - 9 days ago

Genmab announces 5.08% stake by Orbis Investment

Genmab price target lowered to $33 from $34 at Morgan Stanley

2026-05-08T14:43:05.000Z - 9 days ago

Genmab price target lowered to $33 from $34 at Morgan Stanley

Q1 2026 Genmab A/S Earnings Call Transcript

2026-05-08T06:18:44.000Z - 9 days ago

Q1 2026 Genmab A/S Earnings Call Transcript

Genmab reports Q1 operating profit $180M, consensus $172.7M

2026-05-07T17:58:45.000Z - 10 days ago

Genmab reports Q1 operating profit $180M, consensus $172.7M

Genmab maintains FY26 guidance

2026-05-07T17:58:06.000Z - 10 days ago

Genmab maintains FY26 guidance

Genmab Earnings Call Transcript: Q1 2026

May 7, 2026, 12:00 PM EDT - 10 days ago

Genmab Earnings Call Transcript: Q1 2026

Genmab A/S Reveals Drop In Q1 Income

2026-05-07T15:30:00.000Z - 10 days ago

Genmab A/S Reveals Drop In Q1 Income

Genmab Announces Financial Results for the First Quarter of 2026

Thu, 07 May 2026 11:02:00 -0400 - 10 days ago

Genmab Announces Financial Results for the First Quarter of 2026

What To Expect From Genmab AS (GMAB) Q1 2026 Earnings

2026-05-06T13:17:40.000Z - 11 days ago

What To Expect From Genmab AS (GMAB) Q1 2026 Earnings

Genmab price target lowered to $38 from $40 at H.C. Wainwright

2026-04-30T10:16:26.000Z - 17 days ago

Genmab price target lowered to $38 from $40 at H.C. Wainwright

Genmab upgraded to Outperform from Neutral at BNP Paribas

2026-04-22T09:26:15.000Z - 25 days ago

Genmab upgraded to Outperform from Neutral at BNP Paribas

Genmab upgraded to Buy from Neutral at Goldman Sachs

2026-04-22T08:31:06.000Z - 25 days ago

Genmab upgraded to Buy from Neutral at Goldman Sachs

Genmab A/S Share Capital Reduction

Fri, 17 Apr 2026 10:56:00 -0400 - 4 weeks ago

Genmab A/S Share Capital Reduction

Genmab Reports Strong Q1 DARZALEX Sales Near $4 Bln

2026-04-14T17:17:09.000Z - 4 weeks ago

Genmab Reports Strong Q1 DARZALEX Sales Near $4 Bln

Major Shareholder Announcement

Tue, 14 Apr 2026 10:44:00 -0400 - 4 weeks ago

Major Shareholder Announcement

Genmab reports Darzalex Q1 worldwide sales $3.964B

2026-04-14T10:32:06.000Z - 4 weeks ago

Genmab reports Darzalex Q1 worldwide sales $3.964B

JNJ

Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2026

2026-04-14T10:24:00.000Z - 4 weeks ago

Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2026

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026

Tue, 14 Apr 2026 06:23:00 -0400 - 4 weeks ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026

Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2026

2026-04-14T10:23:00.000Z - 4 weeks ago

Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2026

Genmab (GMAB) Unveils Encouraging Data on New Ovarian Cancer Treatment

2026-04-13T15:27:07.000Z - 4 weeks ago

Genmab (GMAB) Unveils Encouraging Data on New Ovarian Cancer Treatment

Genmab presents safety, tolerability data on Rina-S with bevacizumab

2026-04-13T13:51:01.000Z - 4 weeks ago

Genmab presents safety, tolerability data on Rina-S with bevacizumab

Genmab A/S: Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S) in Combination with Bevacizumab in Advanced Ovarian Cancer

2026-04-13T13:36:00.000Z - 4 weeks ago

Genmab A/S: Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S) in Combination with Bevacizumab in Advanced Ovarian Cancer

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer

Mon, 13 Apr 2026 09:35:00 -0400 - 4 weeks ago

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer

Mon, 13 Apr 2026 09:35:00 -0400 - 4 weeks ago

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Apr 1, 2026, 3:19 PM EDT - 6 weeks ago

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

GMAB

Major Shareholder Announcement

Apr 1, 2026, 3:24 AM EDT - 6 weeks ago

Major Shareholder Announcement

GMAB

Genmab initiated with an Outperform at Wolfe Research

2026-03-26T20:16:39.000Z - 7 weeks ago

Genmab initiated with an Outperform at Wolfe Research

Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab

Mar 19, 2026, 2:21 PM EDT - 2 months ago

Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab

GMAB

Genmab A/S Annual Shareholders Meeting Transcript

2026-03-19T18:00:23.000Z - 2 months ago

Genmab A/S Annual Shareholders Meeting Transcript

Passing of Genmab A/S' Annual General Meeting

Mar 19, 2026, 10:06 AM EDT - 2 months ago

Passing of Genmab A/S' Annual General Meeting

GMAB

Completion of Share Buy-back Program

Mar 16, 2026, 10:09 AM EDT - 2 months ago

Completion of Share Buy-back Program

GMAB

Genmab Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 11, 2026, 1:30 PM EDT - 2 months ago

Genmab Transcript: Barclays 28th Annual Global Healthcare Conference

Genmab Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 8:40 AM EDT - 2 months ago

Genmab Transcript: Leerink Global Healthcare Conference 2026

Transactions in Connection with Share Buy-back Program

Mar 9, 2026, 10:01 AM EDT - 2 months ago

Transactions in Connection with Share Buy-back Program

GMAB

Genmab Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 9:10 AM EST - 2 months ago

Genmab Transcript: TD Cowen 46th Annual Health Care Conference

Correction to Company Announcement No. 13 of March 2, 2026

Mar 2, 2026, 4:53 PM EST - 2 months ago

Correction to Company Announcement No. 13 of March 2, 2026

GMAB

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Mar 2, 2026, 2:58 PM EST - 2 months ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

GMAB

Genmab initiated with an Overweight at Wells Fargo

2026-03-02T11:06:13.000Z - 2 months ago

Genmab initiated with an Overweight at Wells Fargo

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

Feb 27, 2026, 3:21 PM EST - 2 months ago

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

GMAB

Genmab to Participate in Upcoming Investor Conferences

Feb 25, 2026, 10:27 AM EST - 2 months ago

Genmab to Participate in Upcoming Investor Conferences

GMAB

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Feb 24, 2026, 3:20 PM EST - 2 months ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GMAB

Genmab price target lowered to $40 from $45 at Guggenheim

2026-02-23T11:38:03.000Z - 2 months ago

Genmab price target lowered to $40 from $45 at Guggenheim

Top 3 Health Care stocks That Could Lead To Your Biggest Gains In Q1

Feb 19, 2026, 6:21 AM EST - 3 months ago

Top 3 Health Care stocks That Could Lead To Your Biggest Gains In Q1

GMAB HSTM SDGR

Notice to Convene the Annual General Meeting of Genmab A/S

Feb 18, 2026, 9:09 AM EST - 3 months ago

Notice to Convene the Annual General Meeting of Genmab A/S

GMAB

Genmab price target raised to $40 from $39 at H.C. Wainwright

2026-02-18T11:10:34.000Z - 3 months ago

Genmab price target raised to $40 from $39 at H.C. Wainwright

Genmab Announces Initiation of Share Buy-Back Program

Feb 17, 2026, 3:14 PM EST - 3 months ago

Genmab Announces Initiation of Share Buy-Back Program

GMAB

Genmab Earnings Call Transcript: Q4 2025

Feb 17, 2026, 12:00 PM EST - 3 months ago

Genmab Earnings Call Transcript: Q4 2025

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Feb 17, 2026, 11:23 AM EST - 3 months ago

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Genmab sees 2026 revenue $4.065B-$4.395B, consensus $4.13B

2026-02-17T16:10:16.000Z - 3 months ago

Genmab sees 2026 revenue $4.065B-$4.395B, consensus $4.13B

HALO JNJ

Genmab Publishes 2025 Annual Report

Feb 17, 2026, 11:01 AM EST - 3 months ago

Genmab Publishes 2025 Annual Report

Genmab resumed with a Buy at Jefferies

2026-02-17T09:30:28.000Z - 3 months ago

Genmab resumed with a Buy at Jefferies

Genmab resumed with an Equal Weight at Morgan Stanley

2026-02-16T12:00:10.000Z - 3 months ago

Genmab resumed with an Equal Weight at Morgan Stanley

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Jan 29, 2026, 12:49 PM EST - 3 months ago

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025

Jan 21, 2026, 6:23 AM EST - 4 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025

Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study

Jan 16, 2026, 1:35 PM EST - 4 months ago

Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study

ABBV

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Jan 16, 2026, 1:31 PM EST - 4 months ago

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence

Jan 7, 2026, 9:00 AM EST - 4 months ago

Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence

Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:58 AM EST - 4 months ago

Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference

Genmab scraps development of experimental cancer therapy

Dec 29, 2025, 9:03 AM EST - 4 months ago

Genmab scraps development of experimental cancer therapy

Genmab Portfolio Prioritization Update

Dec 29, 2025, 8:12 AM EST - 4 months ago

Genmab Portfolio Prioritization Update

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

Dec 12, 2025, 1:36 AM EST - 5 months ago

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

MRUS

Genmab to Hold 2025 R&D Update and ASH Data Review Meeting

Dec 11, 2025, 2:00 AM EST - 5 months ago

Genmab to Hold 2025 R&D Update and ASH Data Review Meeting

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

Dec 8, 2025, 4:30 PM EST - 5 months ago

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

Dec 7, 2025, 7:50 AM EST - 5 months ago

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

Dec 6, 2025, 9:30 AM EST - 5 months ago

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes

Dec 3, 2025, 3:03 PM EST - 5 months ago

Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Dec 1, 2025, 4:24 PM EST - 5 months ago

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami

Nov 24, 2025, 7:00 AM EST - 6 months ago

Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami

Genmab Announces Pricing of Private Offering of Senior Secured Notes and Senior Unsecured Notes and Completion of Syndication of New Senior Secured Term Loan Facility

Nov 18, 2025, 4:01 PM EST - 6 months ago

Genmab Announces Pricing of Private Offering of Senior Secured Notes and Senior Unsecured Notes and Completion of Syndication of New Senior Secured Term Loan Facility

Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

Nov 18, 2025, 11:30 AM EST - 6 months ago

Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes

Nov 10, 2025, 10:51 AM EST - 6 months ago

Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes

Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility

Nov 10, 2025, 7:12 AM EST - 6 months ago

Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility

Genmab to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference in London

Nov 5, 2025, 12:58 PM EST - 6 months ago

Genmab to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference in London

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

Nov 3, 2025, 9:05 AM EST - 6 months ago

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

Oct 23, 2025, 12:43 PM EDT - 7 months ago

Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

MRUS

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Oct 18, 2025, 6:00 AM EDT - 7 months ago

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025

Oct 14, 2025, 6:23 AM EDT - 7 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025

MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

Sep 30, 2025, 9:59 PM EDT - 8 months ago

MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

MRUS

This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired.

Sep 29, 2025, 7:36 AM EDT - 8 months ago

This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired.

MRUS

Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline

Sep 29, 2025, 3:23 AM EDT - 8 months ago

Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline

MRUS

Genmab to buy Dutch cancer drugmaker Merus for $8 billion

Sep 29, 2025, 1:19 AM EDT - 8 months ago

Genmab to buy Dutch cancer drugmaker Merus for $8 billion

MRUS

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

Sep 29, 2025, 1:14 AM EDT - 8 months ago

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

MRUS

10 stocks to consider if you want alternatives to the expensive S&P 500

Sep 9, 2025, 2:39 PM EDT - 8 months ago

10 stocks to consider if you want alternatives to the expensive S&P 500

SPY AEG EFA NGG

Night_Owl_Biotech
Night_Owl_Biotech May. 16 at 3:07 AM
The attachment compares the Year 4 (FY2029), 5-year & 10-year revenue multiples of the 5 largest commercial-stage oncology focused bios using enterprise value. The table uses enterprise value, right or wrong, because cash/debt provides meaningful portions of the cap table of all 5. The table also provides a 5-year gross margin multiple (using actual FY25 gross margin). All 5 have at least 10 analysts that provide FY26 – 30 revenue forecasts. Again, all multiples use enterprise value (not market cap). $INCY clearly trades at the lowest 5-year revenue multiple. This is likely because the patent on Incyte’s best selling therapy called Jakafi expires in December 2028. Still, decreases in Jakafi sales appear to manifest in Incyte’s FY2029 consensus. Incyte still trades at the 2nd lowest 10-year multiple. $EXEL has the highest 5-year revenue multiple in the peer group. This is not investment advice. We’re merely sharing our analysis. $JAZZ $GMAB $ONC
0 · Reply
BlackSwan13
BlackSwan13 May. 13 at 8:23 PM
$GMAB analyzing a position
0 · Reply
The_Assassin
The_Assassin May. 11 at 12:03 PM
$GMAB looks interesting
1 · Reply
Quantumup
Quantumup May. 11 at 11:18 AM
Guggenheim🏁 $BCAX Buy; $42 $GMAB - MRUS $MRK Here's what Guggenheim said in its initiation report: https://x.com/Quantumup1/status/2053796129276358965?s=20
0 · Reply
CapitalMonk
CapitalMonk May. 11 at 9:32 AM
$GMAB Price: $26.43 (-2.33%) Trend: Bearish Market Bias (7D): Bullish Bias 📈 Expected Range: ±1.13% RSI: 39.0 | Momentum: Strong Downside Volume: +217.2% vs avg Volatility: 2.07% Support: $25.34 | Resistance: $29.43 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
QuantInsider
QuantInsider May. 8 at 5:27 PM
$GMAB looking shaky post earnings Stock's down about 3.5% today after that 11% earnings drop Revenue up 25% but profit took a 73% hit thanks to those Merus acquisition costs Interesting move though Spotted 2,900 Dec 2026 $30 calls bought at the ask for around $0.9M, mostly as sweeps 14 to 16% OTM on InsiderFinance Feels like a cautious play on the long-term story With just four prints and a lot of open interest, it’s more of a watch-list situation for now Near-term, the tape's still under pressure Might be wise to wait for some price stabilization before diving in
0 · Reply
peloswing
peloswing May. 8 at 2:31 PM
$GMAB December 18th $30 calls are seeing lots of action today. Potential to double bottom with the March lows 🟢
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 7 at 3:13 PM
$GMAB Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.08 down -74.19% YoY • Reported revenue of $896M up 25.31% YoY • Genmab is maintaining its 2026 financial guidance, expecting revenue in the range of $4.1B and operating profit between $900M, as published February 17, 2026.
0 · Reply
Todd25
Todd25 May. 6 at 9:44 PM
$GMAB when earnings?
0 · Reply
JackDarwin
JackDarwin May. 5 at 7:34 AM
$GMAB Bullish Engulfing Candlestick Pattern Formed at Downtrend. Wait for the confirmation from the next day's candle.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 4 at 1:54 AM
$JAZZ v $GMAB valuation related data points. JAZZ trades at 75-80% of GMAB's valuation yet is expected to generate 90% of GMAB's 5-year forecast. Put simpler, JAZZ trades at 0.60X 5-year analyst consensus while GMAB trades at 0.70X. GMAB's FY25 gross margin was 2% higher than JAZZ & GMAB is digesting its MRUS acquisition. We're curious if $ZYME investors expect a JAZZ buyout at this point? $XBI $IBB
0 · Reply
BioTechHealthX
BioTechHealthX May. 3 at 3:20 PM
$GMAB After a recent pullback, Genmab A/S is being eyed as a value opportunity with major clinical catalysts ahead. With blockbuster drugs, multi-billion-dollar pipelines, and analyst upgrades, investors are watching closely for a potential rebound. https://biotechhealthx.com/biotech-news/is-it-wise-to-consider-investing-in-genmab-a-s-gmab/
0 · Reply
BioTechHealthX
BioTechHealthX May. 1 at 5:09 AM
$ACAD $ARGX $GMAB $HALO $INCY Biotech stocks just delivered their strongest gains since the pandemic, outperforming the S&P 500. Discover the top 10 best biotech stocks to buy now based on profitability, growth, and analyst upgrades. https://biotechhealthx.com/biotech-news/top-10-best-biotech-stocks-wall-street-is-buying-aggressively-now/
0 · Reply
BillionerOfKing
BillionerOfKing Apr. 28 at 2:06 PM
$GMAB Current Stock Price: $26.56 Contracts to trade: $25.0 GMAB May 15 2026 Call Entry: $0.80 Exit: $1.48 ROI: 85% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 28 at 2:45 AM
$GMAB RSI: 42.19, MACD: -0.1147 Vol: 0.86, MA20: 27.71, MA50: 27.65 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SenefAS
SenefAS Apr. 21 at 8:16 PM
$GMAB Genmab a lot of options tonight… Something is cooking 🤔 $NVO $JNJ
1 · Reply
OptionRunners
OptionRunners Apr. 21 at 2:34 PM
$GMAB
0 · Reply
stockwatcherking
stockwatcherking Apr. 21 at 2:26 PM
$GMAB Aggressive $30 call flow here in the August strikes.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 19 at 9:28 PM
Analysts project $JAZZ to generate roughly the same total revenue dollars as $HZNP mgmt/BOD projected for the 5 years after Amgen paid $28.2B to acquire them. Does this suggest JAZZ would be worth about the same if JAZZ were ever acquired? JAZZ generated 92% gross margins in FY25. HZNP projected 85% gross margins over the 5-year period. Does the higher gross margin profile suggest JAZZ would merit a higher multiple than HZNP (all other things being equal). This is not investment advice. All the same, we've wondered how long JAZZ investors will wait before demanding a valuation consistent with their underlying business. Incidentally, $GMAB 5-year analyst consensus are also very close to HZNP (in fact slightly higher 10-year) but we're giving a quarter to 2 to digest their recent acquisition. More on GMAB soon. $XBI $IBB
0 · Reply
Pika_Capital
Pika_Capital Apr. 14 at 1:28 PM
$GMAB cash pile keeps growing. This should be trading at 40 bucks minimum
0 · Reply
SenefAS
SenefAS Apr. 14 at 11:46 AM
$JNJ $GMAB Boommm $4B sales for Darzalex Q1 Genmab & Johnson… Tic tac 🙃
0 · Reply
DonCorleone77
DonCorleone77 Apr. 14 at 10:54 AM
$GMAB Genmab reports Darzalex Q1 worldwide sales $3.964B Genmab (GMAB) announced that worldwide net trade sales of DARZALEX, or daratumumab, including sales of the subcutaneous, or SC, product, daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO in the U.S., as reported by J&J (JNJ), were $3.964B in the Q1. Net trade sales were $2.208M in the U.S. and $1.756M in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to J&J to develop, manufacture and commercialize daratumumab.
0 · Reply